Ultomiris approved in the US for adults with generalised myasthenia gravis
First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalised myasthenia gravis.Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks.Ultomiris (ravulizumab-cwvz) has been approved in the US for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive, which represents 80% of people living with the disease.[1-5] The approval by the Food and Drug